Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Expected to Announce Quarterly Sales of $27.19 Million

Equities analysts expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to post sales of $27.19 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Sangamo Therapeutics’ earnings. The lowest sales estimate is $25.00 million and the highest is $28.00 million. Sangamo Therapeutics posted sales of $57.76 million during the same quarter last year, which would indicate a negative year over year growth rate of 52.9%. The business is scheduled to announce its next earnings results on Wednesday, November 3rd.

On average, analysts expect that Sangamo Therapeutics will report full year sales of $112.38 million for the current financial year, with estimates ranging from $109.81 million to $121.00 million. For the next fiscal year, analysts forecast that the business will report sales of $130.88 million, with estimates ranging from $69.00 million to $307.20 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, August 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). The firm had revenue of $27.87 million for the quarter, compared to the consensus estimate of $29.72 million. Sangamo Therapeutics had a negative net margin of 98.21% and a negative return on equity of 27.99%.

A number of equities research analysts have weighed in on SGMO shares. HC Wainwright began coverage on shares of Sangamo Therapeutics in a report on Thursday, August 26th. They issued a “buy” rating and a $25.00 price objective on the stock. Zacks Investment Research cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Hold” and a consensus target price of $20.80.

Shares of NASDAQ:SGMO opened at $9.28 on Tuesday. Sangamo Therapeutics has a 12 month low of $8.90 and a 12 month high of $19.43. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -9.77 and a beta of 1.66. The company has a 50-day moving average price of $9.79 and a 200-day moving average price of $10.85.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG3 Management LLC bought a new position in Sangamo Therapeutics in the second quarter worth approximately $30,000. Rockefeller Capital Management L.P. raised its position in Sangamo Therapeutics by 2,900.0% in the first quarter. Rockefeller Capital Management L.P. now owns 3,000 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,900 shares during the period. Captrust Financial Advisors raised its position in Sangamo Therapeutics by 31.5% in the first quarter. Captrust Financial Advisors now owns 4,900 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,173 shares during the period. Acadian Asset Management LLC raised its position in Sangamo Therapeutics by 48.5% in the first quarter. Acadian Asset Management LLC now owns 9,925 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 3,240 shares during the period. Finally, Prudential Financial Inc. bought a new position in Sangamo Therapeutics in the second quarter worth approximately $133,000. Institutional investors and hedge funds own 52.41% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.

Featured Article: Understanding Options Trading

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.